Intrinsic Kidney Pathology Following COVID-19 Infection in Children: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Medicine, General & Internal
Contributor:
Henry H.L. Wu

COVID-19 infections resulting in pathological kidney manifestations have frequently been reported in adults since the onset of the global COVID-19 pandemic in December 2019. Gradually, there have been an increased number of COVID-19-associated intrinsic kidney pathologies in children and adolescents reported as well. The pathophysiological mechanisms between COVID-19 and the onset of kidney pathology are not fully known in children; it remains a challenge to distinguish between intrinsic kidney pathologies that were caused directly by COVID-19 viral invasion, and cases which occurred as a result of multisystem inflammatory syndrome due to the infection. 

  • intrinsic kidney pathology
  • COVID-19
  • SARS-CoV-2
  • children
  • adolescents

1. Introduction

The coronavirus disease (COVID-19) that began in 2019 has spiraled into a global pandemic, continuing up to this day, since the identification of the first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) case in Wuhan, China, in December 2019 [1][2]. Whilst data relating to the epidemiology, pathophysiology, risk factors and prognosis of adults with kidney histopathology following acute COVID-19 infection are becoming more well-established, there remains a sizable knowledge gap in our understanding of intrinsic pathological kidney manifestations in children following acute COVID-19 infection [3]. This is likely explained by the fact that children and adolescents only form about 1–2% of all COVID-19 cases reported globally [4].
A novel syndrome, currently termed multisystem inflammatory syndrome in children (MIS-C), has been recognized by clinicians in the United Kingdom since April 2020. It describes previously healthy children presenting with severe systemic inflammatory syndrome following testing positive for a concurrent or recent COVID-19 infection [5]. MIS-C has been shown to be significantly associated with acute kidney injury (AKI) presentations in children, with an incidence of up to 60% being reported in observational studies [6][7]. Active research is being pursued to differentiate pediatric presentations of AKI from MIS-C following COVID-19 infection, and AKI from direct intrinsic kidney injury as a result of primary COVID-19 infection, with overlapping clinical features between these two entities [8]. There is a growing effort to elicit the specific mechanisms of intrinsic kidney pathophysiology following acute COVID-19 infection. Determining these mechanisms could be challenging, due to the ethical limitations of pursuing routine kidney biopsy for children, and the lack of an accurate non-invasive diagnostic test at present [8][9].
Isolated case reports and case series have been published since the onset of the COVID-19 pandemic, describing newfound or relapsed cases of podocytopathy, glomerular disease and other intrarenal pathologies in children following acute COVID-19 infection. Some of these reported cases are kidney-biopsy-proven, whereas others are empirical diagnoses determined through past medical history relating to kidney disease, non-invasive investigations, and responses to treatment.

2. Intrinsic Kidney Pathology Following COVID-19 Infection in Children

2.1. New-Onset and Relapsed Nephrotic Syndrome

A total of 20 cases involving children or adolescents presenting with either new-onset or relapsed nephrotic syndrome following acute COVID-19 infection were included in our systematic review (Table 1) [10][11][12][13][14][15][16][17][18]. In 13 of these 20 cases, there was a relapse of a previously known nephrotic syndrome, and detailed data in relation to the patient demographics, clinical presentation, investigation results and outcome were incomplete in the majority of these reported cases. Such data were also complete amongst the seven patients of which this was the first presentation of nephrotic syndrome. The median age was 6.5 (range 3 to 15) years, and there was a predominance of the male gender (five cases). A diverse distribution of ethnic origin was observed. None of the 20 patients in these nephrotic cases had kidney biopsy during hospital admission, and diagnoses were made empirically, based on clinical presentation of systemic edema (abdominal distension, facial swelling, and/or lower limb edema) and nephrotic-range proteinuria. Standard treatment included oral steroid therapy in addition to supportive treatment (albumin infusion and diuresis). All of the reported cases achieved remission of nephrotic syndrome following acute treatment.
Table 1. Demographics and outcomes of children and adolescents with new-onset and relapsed nephrotic syndrome following acute COVID-19 infection.
Author(s) and Country of Report Age (yrs) Sex Ethnicity Comorbidities New-onset or Relapse Clinical
Presentation		 Presentation Creatinine (mg/dL) Presentation
Proteinuria (g/day)		 Presentation Albumin (g/dL) Haematuria Kidney Biopsy Treatment Received Clinical Outcome
Alvarado et al. [10]
Ecuador		 15 M Not Known Nil New-Onset Anasarca,
Dyspnoea,
Oliguria		 0.55 3.9 1.5 Nil Not done as inpatient. To be scheduled as outpatient Chloroquine and Azithromycin, daily boluses of methylprednisolone for 5 doses Resolution of oedema
Shah et al. [11]
United States		 8 M Not Known Nil New-Onset Facial swelling, pedal/scrotal oedema 0.32 11.4 2 Yes, 2+ blood on urinalysis No Oral Prednisolone and supportive treatment Achieved remission, continued oral prednisolone on reporting
Morreale et al. [12]
Italy		 3 Not Known Italian, born to non-consanguineous parents Nil New-Onset Abdominal distension/lower limb oedema Not Known 0.4 1.6 Nil No Oral Prednisolone, Intravenous Albumin on Day 1, Furosemide from Day 3 Prednisolone and furosemide were gradually tapered with disease remission
Morgan et al. [13]
United States		 5 F Not Known Nil New-Onset Abdominal distension/ lower limb oedema 0.27 >12 2 Nil No Intravenous albumin and furosemide for diuresis, oral vitamin D and oral corticosteroids Achieved complete remission within 3 weeks of starting corticosteroids and urine protein was still negative after 6 weeks of therapy
Basalely et al. [14]
United States		 Not Known M Hispanic Steroid-sensitive Nephrotic Syndrome with infrequent relapses Relapse Anasarca 0.5 18.7 <2.0 Moderate blood, 4–10 RBC, +hyaline casts No Received IV Abx. Blood Cultures +ve for Strep. Agalactiae, Stress-dose IV Hydrocortisone followed by oral Prednisolone, IV Albumin and IV Furosemide, prophylactic VTE treatment Completed 10 days Abx treatment and 2 weeks of prophylactic VTE treatment alongside oral Prednisolone
Enya et al. [15]
Japan		 3 M Japanese Nephrotic Syndrome, Family Hx of Familial
Hyper-
cholesterolemia		 Relapse Eyelid oedema 0.18 6.3 3.5 Nil No Commenced on oral Prednisolone, otherwise supportive management Achieved remission after a week of treatment
Al-Yazidi et al. [16]
Oman		 10 M Arabic (Oman) Steroid-sensitive Nephrotic Syndrome Relapse Facial edema, abdominal distension Not Known Not Known Not Known Nil No Commenced on oral Prednisolone, and required albumin infusion Tapering of oral Prednisolone dose with resolution of proteinuria
Melgosa et al. [17]
Spain
(2 patients)		   2 patients with steroid-dependent nephrotic syndrome with acute COVID-19 infection provoked a relapse of their nephrotic syndrome. Both patients recovered following administration of oral Prednisolone without complications. Data were not described for each of these 2 patients individually.
Krishnasamy
et al. [18]
India
(11 patients)		   11 out of 24 patients with previous diagnosis of nephrotic syndrome developed relapse of their nephrotic syndrome following acute COVID-19 infection. Data and outcomes were not described for each of these 11 patients individually.
Abx, antibiotics; COVID-19, coronavirus disease 2019; F, female; IV, intravenous; M, male; RBC, red blood cells; VTE, venous thromboembolism.

2.2. Glomerulonephritis and Hemolytic-Uremic Syndrome

Basiratnia et al. [19] reported two cases of adolescent boys, aged 16 and 17 years, presenting with AKI in association with a concurrent acute COVID-19 infection. Urinalysis displayed frank hematoproteinuria on presentation, and kidney biopsies were performed in both cases. Histopathological evaluation of the kidney biopsies showed acute necrotizing glomerulonephritis with fibrocellular crescents. Anti-neutrophil cytoplasmic antibodies (ANCAs) and anti-glomerular basement membrane (anti-GBM) results were not reported. Both patients required acute hemodialysis and were commenced on high-dose steroid therapy. The 16-year-old boy achieved full recovery of kidney function and remained dialysis independent. However, the 17-year-old boy required maintenance dialysis following discharge.
A 17-year-old boy with recent hospital admission in relation to COVID-19 pneumonia (receiving dexamethasone, remdesivir and azithromycin during that admission) was re-admitted one month following his initial hospitalization [20]. He re-presented with AKI and frank hematoproteinuria, which was treated as pre-renal AKI and the patient achieved complete kidney function recovery. A month after this second acute presentation, he further re-presented with acute shortness of breath and cough symptoms, although his COVID-19 RT-PCR test was negative when rechecked. Computed tomography of the chest was suggestive of pulmonary hemorrhage, after which bronchoalveolar lavage confirmed this finding. Serum testing revealed severe AKI, and further immunology screening detected positivity for the perinuclear anti-neutrophil cytoplasmic antibody (P-ANCA) and myeloperoxidase (MPO) antibodies. With vasculitis being the presumed diagnosis, a kidney biopsy was performed which revealed necrotizing glomerulonephritis. The patient required acute hemodialysis, and was treated with plasmapheresis, steroid therapy and cyclophosphamide. Full resolution of AKI was achieved during this hospital admission, and he remained dialysis independent following discharge.
Relapse of recurrent anti-factor H antibody-associated atypical hemolytic uremic syndrome (aHUS) with an underlying complement factor H-related protein mutation was found in a 10-year-old boy with a positive COVID-19 infection diagnosis through nuclear antibody testing [21]. The patient presented with frank proteinuria and commenced oral steroid therapy and mycophenolate mofetil during his hospital admission. He also received two doses of intravenous rituximab, and required intravenous immunoglobulin. The patient was discharged with end-stage kidney disease, requiring maintenance hemodialysis and regular oral steroid therapy.

2.3. Transplant Intrinsic Kidney Pathologies

Regarding children and adolescents with transplanted kidneys (Table 1), a case of collapsing glomerulopathy (CG) with concurrent chronic antibody-mediated rejection, and another case of T-cell-mediated rejection, were reported in association with acute COVID-19 infection for two adolescents aged 15 and 16 years, respectively [22][23]. In both of these cases, the patients required meticulous optimization of their immunosuppression medications, alongside supportive medical management to reduce the risk of further COVID-19-associated complications. Another two cases in patients with recent kidney transplants were found to have COVID-19 RT-PCR positive test results on day 2 and day 105 after their operations, respectively [24]. Both patients did not display clear-cut kidney pathological manifestations following the COVID-19 infection diagnosis, with the kidney biopsy finding < 10% tubular interstitial infiltration in one patient, and microcalcifications in the other. Both patients remained largely asymptomatic following, and were managed supportively.
Table 1. Demographics and outcomes of children and adolescents with transplant intrinsic kidney pathologies following acute COVID-19 infection.
Author and Country of Report Age (yrs) Sex Ethnicity Comorbidities Pathology New-Onset or Relapse Presentation Creatinine (mg/dL) Presentation Proteinuria (g/Day) Presentation Albumin (g/dL) RBC per High Powered Field Kidney Biopsy Treatment Received Clinical Outcome
Levenson et al. [22]
United States		 16 M Black Remote cerebrovascular accident,
ESKD secondary to microscopic polyangitis (pANCA vasculitis),
live-donor transplant recipient-previous acute antibody rejection		 Collapsing Glomerulopathy New-Onset 2.3 and increasing to 4.7
(baseline 1.5)		 17 1.2 Nil Yes Acute discontinuation of MMF, required two doses of IV immunoglobulin supportive treatment otherwise Recovery of graft function, discharged DI,
MMF increased back to regular doses
Daniel et al. [23]
United States		 15 F Hispanic ESKD secondary to decreased nephron mass. Patient received deceased donor kidney transplantation T-cell-mediated rejection New-Onset 2.1 (baseline is 0.5) 0.31 4 272 Yes Steroids and Bamlanvimab was administered as post COVID-19 therapy Discharged with some recovery of graft function.
Berteloot et al. [24]
France
(2 patients)		 2 patients with positive COVID-19 RT-PCR results following kidney transplantation on day 2 and day 105, respectively, were described. Patient 1 had ESKD secondary to HUS, and received a deceased donor transplant. Patient 2 had CKDu, and also received a deceased donor transplant. Transplant kidney biopsy revealed <10% tubular interstitial infiltration in patient 1 and microcalcifications in patient 2. Both patients remained asymptomatic with the positive COVID-19 RT-PCR result.
COVID-19, coronavirus disease 2019; CKDu, chronic kidney disease of unknown aetiology; DI, dialysis independent; ESKD, end-stage kidney disease; HUS, Hemolytic Uremic Syndrome; MMF, mycophenolate mofetil; pANCA, perinuclear anti-neutrophil cytoplasmic antibody.

3. Summary

Nephrotic syndrome appeared as the most frequently reported clinical presentation. Nephrotic syndrome is a common kidney pathology observed in children and adolescents, characterized by minimal change disease in the majority (more than 80%) [25][26]. It is defined by the inability to restrict urinary protein loss, due to alterations of perm-selectivity in the capillary walls of the glomerulus, as a result of podocyte injury. Nephrotic-range proteinuria is recognized as the equivalent of 3.5 g or more of protein identified from a 24-h urine sample collection (urine protein-creatinine ratio > 300 mg/mmol), and childhood nephrotic syndrome tends to be selective towards albuminuria [27]. In children and adolescents, approximately 95% of nephrotic syndrome presentations are idiopathic, with the remaining 5% secondary to causes such as viral diseases (e.g., Parvovirus B19, Human Immunodeficiency Virus (HIV), Hepatitis B and C), inflammatory conditions (e.g., Juvenile Idiopathic Arthritis) or rare conditions such as Amyloidosis and Henoch–Schonlein Purpura [28][29][30][31][32][33]. Although COVID-19-associated minimal-change nephrotic syndrome is increasingly reported, its epidemiology in comparison with those minimal change cases induced by other viral infections remains unclear at this point in time. The mechanisms of how COVID-19 might induce nephrotic syndrome have been postulated in several adult studies, but there is very limited data for comparison in children and adolescents. A study conducted in China by Su et al. [34], with post-mortem kidney biopsy samples, found SARS-CoV-2 virion particles in podocytes with effaced foot-processes, suggestive of direct podocytopathic injury. Another report found evidence of tubuloreticular inclusions, often a marker of viral replication and marked interferon production within endothelial cells in the glomerulus [35]. These results have been disputed, with suggestions that the ultrastructural histological findings were actually normal subcellular structures, such as clathrin-coated vesicles and multivesicular bodies [36][37]. An alternative perspective on the mechanism of COVID-19-induced nephrotic syndrome advocates that it is mediated by multiple immunological pathways. Results from basic science studies during the early days of the pandemic suggest tissue damage from SARS-CoV-2 virus is defined by the generation of a cytokine storm [38]. It is believed that podocytopathy can be triggered by the cytokine storm generating an immunological milieu with excessive production of Th2-generated cytokines. Though there are ethical controversies to consider, it was a limitation that there were no kidney biopsy-proven histopathologies from the nephrotic syndrome presentations reviewed. In steroid-sensitive nephrotic syndrome, which represents almost 99% of all idiopathic nephrotic syndrome cases in children aged 1–12 years, kidney biopsy is not usually performed unless a child does not achieve remission following a 4-week course of steroids [39]. Mechanistic associations between COVID-19 infection and nephrotic syndrome in children and adolescents may have been further ascertained with evaluation of kidney biopsy findings.

Various glomerulonephritides have been reported in children and adolescents following COVID-19 infection. CG is a variant of Focal Segmental Glomerulosclerosis (FSGS), characterized by glomerular tuft collapse, segmentally or globally [40][41][42]. CG has previously been reported to associate with multiple infections and inflammatory conditions, namely HIV and systemic lupus erythematous [43]. Previous reviews evaluating COVID-19 induced glomerular disease in adults suggest CG to be amongst the most prevalent histopathological presentations [3][44]. The pathogenesis of CG is currently believed to be a multifactorial process associated with both direct viral invasion of glomerular structures and cytokine release [45][46]. Adult individuals of Afro-Caribbean ethnicity, and those carrying the APOL1 high-risk genotype have been shown to be at higher risk of CG following acute COVID-19 infection, due to stimulation of interferon production encouraging APOL1 gene expression [45][46].
AKI secondary to acute necrotizing glomerulonephritis and vasculitis in acute COVID-19 infection is hypothesized to be caused by glomerular hypoperfusion and tubular necrosis, leading to fibrinoid necrosis within the glomerulus and arterial walls of the intrarenal vessels [47][48]. Neutrophil extracellular trap (NET) formation, as part of the innate inflammatory process of acute COVID-19 infection, has been hypothesized to play a major role in ANCA antibody formation, by affecting an individual’s immunotolerance during the acute inflammatory state of COVID-19 infection [49]. It is proposed that NET formation is the ultimate source of presentation of MPO and proteinase 3 antigen within this context [49].
In addition, aHUS following COVID-19 infection is thought to be caused by a prothrombotic state, as a result of complement-mediated inflammation and thrombotic microangiopathy-associated processes [50][51]. Models of mice with complement 3 deficiency have shown reduced respiratory distress and pulmonary inflammation, after infection with severe acute respiratory syndrome coronavirus (SARS-CoV), whilst Middle Eastern respiratory syndrome coronavirus (MERS-CoV) infection and elevated levels of C5a and C5a-9 complexes have also been previously demonstrated in mice models [52][53]. These limited findings provide evidence of the significant role played by the complement system in generating hyperinflammatory responses during coronavirus-associated infections. Further work needs to be conducted to validate the role of complement in COVID-19, and its correlation with the onset of thrombotic microangiopathies.
Poorer outcomes following COVID-19 infection in children and adolescents with prior kidney transplantation are expected due to chronic immunosuppression and other co-existing co-morbidities, such as diabetes, mellitus and hypertension, now recognized as significant risk factors for mortality following acute COVID-19 infection [54][55][56]. Due to the lack of reported cases, the precise mechanisms of how acute COVID-19 infection causes kidney transplant rejection and other transplant-associated conditions in children and adolescents requires further exploration. The lack of reported cases may be attributed to the fact that during the first wave of the COVID-19 pandemic, many children with transplanted kidneys were shielding with schools being closed. In our region, the North West of the UK, this has resulted in an extremely low incidence of COVID-19 within this population due to infrequent testing of COVID-19 status.
There remain knowledge gaps in our understanding of the mechanisms associating intrinsic kidney pathologies and COVID-19 infection. Incomplete data regarding kidney histopathology due to limitations in performing kidney biopsy and other invasive investigations for many cases involving children and adolescents has contributed to this. There was a published case series of AKI presentations with proteinuria and hematuria in children and adolescents, following positive COVID-19 PCR results [57]. However, these cases were not included in our systematic review, due to the lack of diagnoses provided from these reports. In other instances, it is difficult to clearly delineate and distinguish the differences between intrinsic kidney pathology caused by MIS-C, and cases that result from a direct viral invasion from COVID-19. Questions remain regarding whether genuine cases of COVID-19 infection-related kidney disease have been missed due to mistimed testing. There have been cases where the appearance of new-onset kidney pathology could not be directly attributed to acute COVID-19 infection, although the patient’s clinical presentation and timeline supported the likelihood of COVID-19-associated illness [58]. Whilst the co-morbidity status of children and adolescents may associate with greater risks of developing these manifestations following COVID-19 infection, in particular for relapsed rather than new-onset kidney disease, further work is required to determine the mechanisms by which acute COVID-19 infection induces renal disease, and to what extent these presentations are impacted by the presence of other confounding factors. The variations in clinical and pathological intrinsic kidney manifestations are currently difficult to explain, due to the relative novelty and lack of case numbers.

This entry is adapted from the peer-reviewed paper 10.3390/children9010003

References

  1. World Health Organization. Pneumonia of Unknown Cause. 2020. Available online: https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON229 (accessed on 10 November 2021).
  2. World Health Organization. WHO Coronavirus disease (COVID-19) dashboard. Available online: https://covid19.who.int/ (accessed on 10 November 2021).
  3. Jeyalan, V.; Storrar, J.; Wu, H.H.L.; Ponnusamy, A.; Sinha, S.; Kalra, P.A.; Chinnadurai, R. Native and transplant kidney histopathological manifestations in association with COVID-19 infection: A systematic review. World J. Transpl. 2021, 11, 480–502.
  4. Qiu, H.; Wu, J.; Hong, L.; Luo, Y.; Song, Q.; Chen, D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: An observational cohort study. Lancet Infect. Dis. 2020, 20, 689–696.
  5. Royal College of Paediatrics and Child Health: Guidance: Paediatric Multisystem Inflammatory Syndrome Temporally Associated with COVID-19. 2020. Available online: https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-%20inflammatory%20syndrome-20200501.pdf (accessed on 10 November 2021).
  6. Godfred-Cato, S.; Bryant, B.; Leung, J.; Oster, M.E.; Conklin, L.; Abrams, J.; Roguski, K.; Wallace, B.; Prezzato, E.; Koumans, E.H.; et al. COVID-19–associated multisystem inflammatory syndrome in children—United States, March–July 2020. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 1074–1080.
  7. González-Dambrauskas, S.; Vásquez-Hoyos, P.; Camporesi, A.; Díaz-Rubio, F.; Piñeres-Olave, B.E.; Fernández-Sarmiento, J.; Gertz, S.; Harwayne-Gidansky, I.; Pietroboni, P.; Shein, S.L.; et al. Pediatric critical care and COVID-19. Pediatrics 2020, 146, e20201766.
  8. Rowley, A.H. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat. Rev. Immunol. 2020, 20, 453–454.
  9. Alshami, A.; Roshan, A.; Catapang, M.; Jöbsis, J.J.; Kwok, T.; Polderman, N.; Sibley, J.; Sibley, M.; Mammen, C.; Matsell, D.G. Indications for kidney biopsy in idiopathic childhood nephrotic syndrome. Pediatr. Nephrol. 2017, 32, 1897–1905.
  10. Alvarado, A.; Franceschi, G.; Resplandor, E.; Sumba, J.; Orta, N. COVID-19 associated with onset nephrotic syndrome in a pediatric patient: Coincidence or related conditions? Pediatr. Nephrol. 2021, 36, 205–207.
  11. Shah, S.A.; Carter, H.P. New-onset nephrotic syndrome in a child associated with COVID-19 infection. Front. Pediatr. 2020, 8, 471.
  12. Morreale, A.; Casciana, M.L. Onset of nephrotic syndrome concomitant to SARS-CoV-2 infection in a 3-year-old child. Pediatr. Nephrol. 2021, 37, 225.
  13. Morgan, K.M.; Imani, P.D. Case report: A 5-year-old with new onset nephrotic syndrome in the setting of COVID-19 infection. BMC Nephrol. 2021, 22, 323.
  14. Basalely, A.; Brathwaite, K.; Duong, M.D.; Liu, D.; Mazo, A.; Xie, Y.; Del Rio, M.; Goilav, B.; Hayde, N.; Kaskel, F.J.; et al. COVID-19 in children with kidney disease: A report of 2 cases. Kidney Med. 2021, 3, 120–123.
  15. Enya, T.; Morimoto, Y.; Oshima, R.; Miyazaki, K.; Miyazawa, T.; Okada, M.; Sugimoto, K. Nephrotic syndrome relapse in a boy with COVID-19. CEN Case Rep. 2021, 10, 431–434.
  16. Al Yazidi, L.; Al Nabhani, D. Coronavirus disease-2019 in children with nephrotic syndrome. Saudi J. Kidney Dis. Transpl. 2021, 32, 284–285.
  17. Melgosa, M.; Madrid, A.; Alvárez, O.; Lumbreras, J.; Nieto, F.; Parada, E.; Perez-Beltrán, V. SARS-CoV-2 infection in Spanish children with chronic kidney pathologies. Pediatr. Nephrol. 2020, 35, 1521–1524.
  18. Krishnasamy, S.; Mantan, M.; Mishra, K.; Kapoor, K.; Brijwal, M.; Kumar, M.; Sharma, S.; Swarnim, S.; Gaind, R.; Khandelwal, P.; et al. SARS-CoV-2 infection in children with chronic kidney disease. Pediatr. Nephrol. 2021; .
  19. Basiratnia, M.; Derakhshan, D.; Yeganeh, B.S.; Derakhshan, A. Acute necrotizing glomerulonephritis associated with COVID-19 infection: Report of two pediatric cases. Pediatr. Nephrol. 2021, 36, 1019–1023.
  20. Fireizen, Y.; Shahriary, C.; Imperial, M.E.; Randhawa, I.; Nianiaris, N.; Ovunc, B. Pediatric P-ANCA Vasculitis following COVID-19. Pediatr. Pulmonol. 2021, 56, 3422–3424.
  21. Meshram, A.; Vala, K.B.; Saha, A.; Patel, H.V.; Kute, V.; Gera, D. Coronavirus Disease-2019 in Children with Primary Kidney Disease: A Case series. Saudi J. Kidney Dis. Transpl. 2021, 32, 218–222.
  22. Levenson, E.; Shepherd, T.N.; Aviles, D.; Craver, R.; Ehlayel, A.; Love, G.L.; Simms, K.J.; Straatmann, C.; Ashoor, I.F. De novo collapsing glomerulopathy in a pediatric kidney transplant recipient with COVID-19 infection. Pediatr. Transpl. 2021, 25, e14013.
  23. Daniel, E.; Sekulic, M.; Kudose, S.; Kubin, C.; Ye, X.; Shayan, K.; Patel, A.; Cohen, D.J.; ERatner, L.; Santoriello, D.; et al. Kidney allograft biopsy findings after COVID-19. Am. J. Transpl. 2021; .
  24. Berteloot, L.; Berthaud, R.; Temmam, S.; Lozach, C.; Zanelli, E.; Blanc, T.; Heloury, Y.; Capito, C.; Chardot, C.; Sarnacki, S.; et al. Arterial abnormalities identified in kidneys transplanted into children during the COVID-19 pandemic. Am. J. Transpl. 2021, 21, 1937–1943.
  25. Noone, D.G.; Iijima, K.; Parekh, R. Idiopathic nephrotic syndrome in children. Lancet 2018, 392, 61–74.
  26. Meyrier, A.; Niaudet, P. Acute kidney injury complicating nephrotic syndrome of minimal change disease. Kidney Int. 2018, 94, 861–869.
  27. Eddy, A.A.; Symons, J.M. Nephrotic syndrome in childhood. Lancet 2003, 362, 629–639.
  28. Ohtomo, Y.; Kawamura, R.; Kaneko, K.; Yamashiro, Y.; Kiyokawa, N.; Taguchi, T.; Mimori, K.; Fujimoto, J. Nephrotic syndrome associated with human parvovirus B19 infection. Pediatr. Nephrol. 2003, 18, 280–282.
  29. Kimmel, P.L.; Ferreira-Centeno, A.; Farkas-Szallasi, T.; Abraham, A.A.; Garrett, C.T. Viral DNA in microdissected renal biopsy tissue from HIV infected patients with nephrotic syndrome. Kidney Int. 1993, 43, 1347–1352.
  30. Gupta, A.; Quigg, R.J. Glomerular diseases associated with hepatitis B and C. Adv. Chronic Kidney Dis. 2015, 22, 343–351.
  31. Kari, J. Steroid-sensitive nephrotic syndrome and juvenile idiopathic arthritis. Pediatr. Nephrol. 2002, 11, 975–976.
  32. Bilginer, Y.; Akpolat, T.; Ozen, S. Renal amyloidosis in children. Pediatr. Nephrol. 2011, 26, 1215–1227.
  33. Tan, J.; Tang, Y.; Xu, Y.; Yan, S.; Xu, Y.; Tan, L.; Zhong, Z.; Tarun, P.; Qin, W. The clinicopathological characteristics of Henoch-Schönlein purpura nephritis with presentation of nephrotic syndrome. Kidney Blood Press. Res. 2019, 44, 754–764.
  34. Su, H.; Yang, M.; Wan, C.; Yi, L.X.; Tang, F.; Zhu, H.Y.; Yi, F.; Yang, H.C.; Fogo, A.B.; Nie, X.; et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020, 98, 219–227.
  35. Larsen, C.P.; Bourne, T.D.; Wilson, J.D.; Saqqa, O.; Sharshir, M.D. Collapsing glomerulopathy in a patient with COVID-19. Kidney Int. Rep. 2020, 5, 935–939.
  36. Miller, S.E.; Brealey, J.K. Visualization of coronavirus in kidney. Kidney Int. 2020, 98, 231–232.
  37. Calomeni, E.; Satoskar, A.; Ayoub, I.; Brodsky, S.; Rovin, B.H.; Nadasdy, T. Multivesicular bodies mimicking SARS-CoV-2 in patients without COVID-19. Kidney Int. 2020, 98, 233–234.
  38. Ye, Q.; Wang, B.; Mao, J. The pathogenesis and treatment of the ‘cytokine storm’ in COVID-19. J. Infect. 2020, 80, 607–613.
  39. Lombel, R.M.; Gipson, D.S.; Hodson, E.M. Treatment of steroid-sensitive nephrotic syndrome: New guidelines from KDIGO. Pediatr. Nephrol. 2013, 28, 415–426.
  40. Albaqumi, M.; Barisoni, L. Current views on collapsing glomerulopathy. J. Am. Soc. Nephrol. 2008, 19, 1276–1281.
  41. Albaqumi, M.; Soos, T.J.; Barisoni, L.; Nelson, P.J. Collapsing glomerulopathy. J. Am. Soc. Nephrol. 2006, 17, 2854–2863.
  42. Detwiler, R.K.; Falk, R.J.; Hogan, S.L.; Jennette, J.C. Collapsing glomerulopathy: A clinically and pathologically distinct variant of focal segmental glomerulosclerosis. Kidney Int. 1994, 45, 1416–1424.
  43. Laurinavicius, A.; Hurwitz, S.; Rennke, H.G. Collapsing glomerulopathy in HIV and non-HIV patients: A clinicopathological and follow-up study. Kidney Int. 1999, 56, 2203–2213.
  44. Velez, J.C.; Caza, T.; Larsen, C.P. COVAN is the new HIVAN: The re-emergence of collapsing glomerulopathy with COVID-19. Nat. Rev. Nephrol. 2020, 16, 565–567.
  45. Wu, H.; Larsen, C.P.; Hernandez-Arroyo, C.F.; Mohamed, M.M.B.; Caza, T.; Sharshir, M.; Chughtai, A.; Xie, L.; Gimenez, J.M.; Sandow, T.A.; et al. AKI and Collapsing Glomerulopathy Associated with COVID-19 and APOL 1 High-Risk Genotype. J. Am. Soc. Nephrol. 2020, 31, 1688–1695.
  46. Ossina, N.K.; Cannas, A.; Powers, V.C.; Fitzpatrick, P.A.; Knight, J.D.; Gilbert, J.R.; Shekhtman, E.M.; Tomei, L.D.; Umansky, S.R.; Kiefer, M.C. Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J. Biol. Chem. 1997, 272, 16351–16357.
  47. Suso, A.S.; Mon, C.; Oñate Alonso, I.; Galindo Romo, K.; Juarez, R.C.; Ramírez, C.L.; Sánchez Sánchez, M.; Mercado Valdivia, V.; Ortiz Librero, M.; Oliet Pala, A.; et al. IgA Vasculitis with Nephritis (Henoch-Schönlein Purpura) in a COVID-19 Patient. Kidney Int. Rep. 2020, 5, 2074–2078.
  48. Iba, T.; Connors, J.M.; Levy, J.H. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm. Res. 2020, 69, 1181–1189.
  49. Uppal, N.N.; Kello, N.; Shah, H.H.; Khanin, Y.; De Oleo, I.R.; Epstein, E.; Sharma, P.; Larsen, C.P.; Bijol, V.; Jhaveri, K.D. De Novo ANCA-Associated Vasculitis with Glomerulonephritis in COVID-19. Kidney Int. Rep. 2020, 5, 2079–2083.
  50. Connors, J.M.; Levy, J.H. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020, 135, 2033–2040.
  51. Risitano, A.M.; Mastellos, D.C.; Huber-Lang, M.; Yancopoulou, D.; Garlanda, C.; Ciceri, F.; Lambris, J.D. Complement as a target in COVID-19? Nat. Rev. Immunol. 2020, 20, 343–344.
  52. Gralinski, L.E.; Sheahan, T.P.; Morrison, T.E.; Menachery, V.D.; Jensen, K.; Leist, S.R.; Whitmore, A.; Heise, M.T.; Baric, R.S. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. MBio 2018, 9, e01753-18.
  53. Jiang, Y.; Zhao, G.; Song, N.; Li, P.; Chen, Y.; Guo, Y.; Li, J.; Du, L.; Jiang, S.; Guo, R.; et al. Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg. Microbes Infect. 2018, 7, 1–2.
  54. Banerjee, D.; Popoola, J.; Shah, S.; Ster, I.C.; Quan, V.; Phanish, M. COVID-19 infection in kidney transplant recipients. Kidney Int. 2020, 97, 1076–1082.
  55. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020, 395, 1054–1062.
  56. Marlais, M.; Wlodkowski, T.; Al-Akash, S.; Ananin, P.; Bandi, V.K.; Baudouin, V.; Boyer, O.; Vásquez, L.; Govindan, S.; Hooman, N.; et al. COVID-19 in children treated with immunosuppressive medication for kidney diseases. Arch. Dis. Child. 2021, 106, 798–801.
  57. Stewart, D.J.; Hartley, J.C.; Johnson, M.; Marks, S.D.; du Pré, P.; Stojanovic, J. Renal dysfunction in hospitalised children with COVID-19. Lancet Child Adolesc. Health 2020, 4, e28–e29.
  58. Plouffe, B.; Van Hooren, T.; Barton, M.; Nashid, N.; Demirkaya, E.; Norozi, K.; Rachinsky, I.; Delport, J.; Knauer, M.; Tole, S.; et al. Renal Infarcts–A Perplexing Case in the Middle of the COVID-19 Pandemic. Front. Pediatr. 2021, 9, 669453.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback